The company has announced that its new investigational device exemption will be used to launch a pivotal trial of its ...

The DETOUR 2 Study included 202 patients across 32 sites, with 200 patients receiving treatment with the DETOUR System.

China: A recent secondary analysis of the CATIS-2 randomized clinical trial has revealed that early initiation of ...

Plus, six other formulas for brighter, smoother skin. I’m actually interested in all seven of Mediheal’s skin care treatment ...

Endologix announced final 36-month results for the DETOUR2 study evaluating its Detour system for treating peripheral ...

Elsewhere in the market of PAD treatment, AngioDynamics has secured a European CE mark for the Auryon Atherectomy System, a laser technology used to treat the illness. "R3 Vascular secures ...

Philips has now developed a device intended to integrate two forms of laser-based PAD therapy, atherectomy and intravascular ...

Elsewhere in the market of PAD treatment, AngioDynamics has secured a European CE mark for the Auryon Atherectomy System, a laser technology used for the treatment of peripheral artery disease (PAD).

Philips announced the first U.S. treatment using its new laser device that combines two peripheral artery disease (PAD) procedures into one.

Walking, in particular, is highly recommended as it helps improve circulation and increases how far someone with PAD can walk without experiencing pain. Medications may also be prescribed to help ...